XML 72 R50.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Summary of Significant Accounting Policies - Schedule of Concentration (Details) | 12 Months Ended
--- | ---
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Janssen | Accounts Receivable | Credit Concentration Risk |  |  |
Product Information [Line Items] |  |  |
Concentration risk percentage | 23.00% |  | 30.00%
Janssen | Revenues Net | Customer Concentration Risk |  |  |
Product Information [Line Items] |  |  |
Concentration risk percentage | 31.00% | 15.00% | 30.00%
Biogen | Accounts Receivable | Credit Concentration Risk |  |  |
Product Information [Line Items] |  |  |
Concentration risk percentage | 9.00% | 19.00% | 11.00%
Biogen | Revenues Net | Customer Concentration Risk |  |  |
Product Information [Line Items] |  |  |
Concentration risk percentage | 11.00% | 13.00% | 10.00%
Cardinal Health | Accounts Receivable | Credit Concentration Risk |  |  |
Product Information [Line Items] |  |  |
Concentration risk percentage | 24.00% | 24.00% | 17.00%
Cardinal Health | Revenues Net | Customer Concentration Risk |  |  |
Product Information [Line Items] |  |  |
Concentration risk percentage | 20.00% | 24.00% | 20.00%
AmerisourceBergen | Accounts Receivable | Credit Concentration Risk |  |  |
Product Information [Line Items] |  |  |
Concentration risk percentage | 16.00% | 18.00% | 13.00%
AmerisourceBergen | Revenues Net | Customer Concentration Risk |  |  |
Product Information [Line Items] |  |  |
Concentration risk percentage | 12.00% | 14.00% | 11.00%
McKesson | Accounts Receivable | Credit Concentration Risk |  |  |
Product Information [Line Items] |  |  |
Concentration risk percentage | 14.00% | 12.00% | 11.00%
McKesson | Revenues Net | Customer Concentration Risk |  |  |
Product Information [Line Items] |  |  |
Concentration risk percentage | 14.00% | 16.00% | 13.00%

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ProductInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_MajorCustomersAxis=alks_JanssenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=alks_RevenuesNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=alks_BiogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=alks_CardinalHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=alks_AmerisourceBergenCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=alks_McKessonCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |